Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 52: 235-239, 2006. First published December 29, 2005; 10.1373/clinchem.2005.050641
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.050641v1
52/2/235    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ulmert, D.
Right arrow Articles by Lilja, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ulmert, D.
Right arrow Articles by Lilja, H.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2006;52:235-239.)
© 2006 American Association for Clinical Chemistry, Inc.


Cancer Diagnostics

Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at –20 °C

David Ulmert1,a, Charlotte Becker1, Jan-Åke Nilsson3, Timo Piironen4, Thomas Björk2, Jonas Hugosson5, Göran Berglund3 and Hans Lilja1,6

1 Department of Laboratory Medicine, Division of Clinical Chemistry, 2 Department of Urology, and 3 Department of Internal Medicine, Lund University, University Hospital (UMAS), Malmö, Sweden.
4 Schering Oy, Turku, Finland.
5 Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden.
6 Departments of Clinical Laboratories, Urology, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.

aAddress correspondence to this author at: Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital (UMAS), S-205 02 Malmö, Sweden. Fax 46-40337043; e-mail David.Ulmert{at}med.lu.se.

Background: Long-term frozen storage may alter the results of prostate-specific antigen (PSA) measurements, mainly because of degradation of free PSA (fPSA) in vitro. We compared the effects of long-term storage on fPSA, total PSA (tPSA), and complexed PSA (cPSA) in serum vs EDTA-plasma samples.

Methods: We measured fPSA and tPSA concentrations in matched pairs of archival serum and EDTA-plasma samples (stored frozen at –20 °C for 20 years) from a large population-based cohort in Malmö, Sweden. We also compared concentrations in age-matched men with those in samples not subjected to long-term storage, obtained from participants in a population-based study of prostate cancer screening in Göteborg, Sweden. These contemporary samples were handled according to standardized preanalytical and analytical protocols aimed at minimizing in vitro degradation. tPSA and fPSA measurements were performed with a commercial assay (Prostatus Dual Assay; Perkin-Elmer Life Sciences).

Results: Concentrations of tPSA and fPSA and calculated cPSA (tPSA – fPSA) in archival plasma were not significantly different from those in contemporary serum from age-matched men. In archival serum, however, random variability of fPSA was higher vs plasma than in contemporary samples, whereas systematic error of fPSA analyses was similarly small in archival and contemporary serum and plasma.

Conclusions: Concentrations of tPSA and calculated cPSA were highly stable in plasma and serum samples subjected to long-term storage at –20 °C. Greater random variability, rather than a systematic decrease, may explain differences in fPSA analyses observed in archival serum.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
L. Zhu, H. Koistinen, U. Landegren, and U.-H. Stenman
Proximity Ligation Measurement of the Complex between Prostate Specific Antigen and {alpha}1-Protease Inhibitor
Clin. Chem., September 1, 2009; 55(9): 1665 - 1671.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
L. Bruun, C. Savage, A. M. Cronin, J. Hugosson, H. Lilja, and A. Christensson
Increase in percent free prostate-specific antigen in men with chronic kidney disease
Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1238 - 1241.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Ulmert, A. M. Serio, M. F. O'Brien, C. Becker, J. A. Eastham, P. T. Scardino, T. Bjork, G. Berglund, A. J. Vickers, and H. Lilja
Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population
J. Clin. Oncol., February 20, 2008; 26(6): 835 - 841.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. Lilja, D. Ulmert, T. Bjork, C. Becker, A. M. Serio, J.-A. Nilsson, P.-A. Abrahamsson, A. J. Vickers, and G. Berglund
Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years
J. Clin. Oncol., February 1, 2007; 25(4): 431 - 436.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. Steuber, A. J. Vickers, A. M. Serio, V. Vaisanen, A. Haese, K. Pettersson, J. A. Eastham, P. T. Scardino, H. Huland, and H. Lilja
Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer
Clin. Chem., February 1, 2007; 53(2): 233 - 240.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.